Posted by Michael Wonder on 23 Mar 2021
Pacira announces FDA approval of supplemental new drug application for Exparel (bupivacaine liposome injectable suspension) in paediatric patients
22 March 2021 - Exparel is the first and only FDA approved long-acting local analgesic for children aged six and over.
Pacira BioSciences today announced the U.S. FDA has approved the submission of its supplemental new drug application seeking expansion of the Exparel label to include use in patients 6 years of age and older for single dose infiltration to produce post surgical local analgesia.
Read Pacira Pharmaceuticals press release
